BioPharm Communications

May 31, 2016 (New York, NY) – Petsky Prunier is pleased to announce that it has advised BioPharm Communications, a leading communications agency that specializes in proprietary, multi-channel marketing programs to physicians and healthcare practitioners for pharmaceutical and biotechnology clients, on its sale to Omnicom Health Group, the largest healthcare marketing and communications group in the world, and part of Omnicom Group Inc. (NYSE: OMC). BioPharm was a portfolio company of Greenwich, CT-based private equity firm Southfield Capital.

Established in 2005 in New Hope, Pennsylvania, BioPharm serves 17 of the 25 largest pharmaceutical companies in the world. With advanced analytic capabilities, BioPharm creates customized campaigns that enable healthcare clients to effectively target their desired audiences, and to engage them with impactful content and relevant clinical information.

Long-time industry veterans and BioPharm co-founders Jeff Persinger and Daniel Egeland will continue in their leadership roles as president/CEO and EVP/chief sales and marketing officer, respectively. In addition, other key executives will maintain their current operating roles, including chief strategy officer Norm Phillips, chief operating officer Steve Carickhoff, and head of analytics Lars Nordmann.

Omnicom Health Group is a global collective of communications companies with more than 3,200 dedicated healthcare communications specialists. It provides marketing services to the health and life-science industries through a combination of specialized agencies, customized client solutions, and collaborations with other Omnicom network agencies. Organized around four customer groups – healthcare professionals, patients, payers, and medical, evidence, and regulatory stakeholders – Omnicom Health Group serves more than 100 clients in 55+ offices worldwide.

A team from Petsky Prunier, led by Christopher French, Sanjay Chadda, and Anil Kuruganti, served as exclusive financial advisor to BioPharm Communications and Southfield Capital.